Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 22, 2026, 7:17 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: TREAT-B Clear all
Terminated Phase 1Phase 2 Interventional Results available

QUILT-3.039: NANT Pancreatic Cancer Vaccine: Combination Immunotherapy in Subjects With Pancreatic Cancer Who Have Progressed on or After Standard-of-care Therapy

NCT03136406
View directory record Official record
Conditions
Pancreatic Cancer
Interventions
Cyclophosphamide, Oxaliplatin, Capecitabine, 5-Fluorouracil, Leucovorin, nab-paclitaxel, bevacizumab, avelumab, ALT-803, aNK for Infusion, ETBX-011, GI-4000
Drug · Biological
Lead sponsor
ImmunityBio, Inc.
Industry
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
El Segundo, California
Source: ClinicalTrials.gov public record
Updated Jun 10, 2024 · Synced Sep 22, 2026, 7:17 PM EDT
Completed Phase 1Phase 2 Interventional Results available

A Study to Evaluate the Safety and Efficacy of CyPep-1 in Combination With Pembrolizumab for the Treatment of Advanced or Metastatic Cancers

NCT05383170
View directory record Official record
Conditions
Advanced Head and Neck Squamous Cell Carcinoma, Advanced Breast Cancer, Advanced Melanoma
Interventions
CyPep-1, Pembrolizumab 25 MG/ML [KEYTRUDA®]
Drug
Lead sponsor
Cytovation AS
Industry
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
6
States / cities
Birmingham, Alabama • Duarte, California • Detroit, Michigan + 3 more
Source: ClinicalTrials.gov public record
Updated Nov 27, 2025 · Synced Sep 22, 2026, 7:17 PM EDT
Active, not recruiting Phase 1 Interventional

A Study of JNJ-90009530 in Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma (r/r B-NHL)

NCT05784441
View directory record Official record
Conditions
Relapsed or Refractory B Cell Non-Hodgkin Lymphoma
Interventions
JNJ-90009530
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2040
U.S. locations
7
States / cities
Iowa City, Iowa • Lexington, Kentucky • Rochester, Minnesota + 4 more
Source: ClinicalTrials.gov public record
Updated Aug 27, 2026 · Synced Sep 22, 2026, 7:17 PM EDT
Completed Phase 2 Interventional

Study of Dynavax's 1018 ISS, Following Rituxan in Patients With B-Cell Follicular Lymphoma

NCT00251394
View directory record Official record
Conditions
Non-Hodgkin's Lymphoma
Interventions
Rituxan, 1018 ISS
Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2009
U.S. locations
3
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 28, 2010 · Synced Sep 22, 2026, 7:17 PM EDT
Active, not recruiting Phase 1 Interventional

Study of INCB123667 in Subjects With Advanced Solid Tumors

NCT05238922
View directory record Official record
Conditions
Solid Tumors
Interventions
INCB0123667, Palbociclib, Bevacizumab, Olaparib, Paclitaxel, Ribociclib, Fulvestrant
Drug
Lead sponsor
Incyte Corporation
Industry
Eligibility
18 Years and older
Enrollment
291 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
18
States / cities
Duarte, California • Irvine, California • Los Angeles, California + 13 more
Source: ClinicalTrials.gov public record
Updated Jul 20, 2026 · Synced Sep 22, 2026, 7:17 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Avatar-Led Digital Therapeutic for Aiding Smoking Cessation in Sexual and Gender Minority Young Adults

NCT05847673
View directory record Official record
Conditions
Cigarette Smoking-Related Carcinoma
Interventions
Online Smoking Cessation Intervention, Questionnaire Administration, Health Promotion and Education
Behavioral · Other
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
18 Years to 30 Years
Enrollment
125 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jul 18, 2024 · Synced Sep 22, 2026, 7:17 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Lifestyle Intervention for High Risk Cancer Survivors

NCT01508273
View directory record Official record
Conditions
Breast Cancer
Interventions
Exercise Program, Website, Exercise DVD, Survey, Self-Report Assessments
Behavioral
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years to 80 Years · Female only
Enrollment
1,150 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2015
U.S. locations
3
States / cities
Fort Worth, Texas • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Dec 1, 2016 · Synced Sep 22, 2026, 7:17 PM EDT
Terminated Phase 2 Interventional Results available

Efficacy, Safety and Tolerability of the Combination of Tropifexor & Licogliflozin and Each Monotherapy, Compared With Placebo in Adult Patients With NASH and Liver Fibrosis.

NCT04065841
View directory record Official record
Conditions
Non Alcoholic Steatohepatitis (NASH)
Interventions
Tropifexor, Licogliflozin, Placebo
Drug · Other
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
234 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
28
States / cities
Dothan, Alabama • Coronado, California • Los Angeles, California + 23 more
Source: ClinicalTrials.gov public record
Updated Jan 27, 2025 · Synced Sep 22, 2026, 7:17 PM EDT
Active, not recruiting Phase 2 Interventional

A Study to Assess Disease Activity and Safety of Subcutaneous Lutikizumab (ABT-981) in Adult Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-Tumor Necrosis Factor (TNF) Therapy and Who Are Naïve to Biologic Therapy

NCT05139602
View directory record Official record
Conditions
Hidradenitis Suppurativa
Interventions
Lutikizumab, Placebo
Biological · Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years and older
Enrollment
210 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
25
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Hot Springs, Arkansas + 20 more
Source: ClinicalTrials.gov public record
Updated Feb 12, 2026 · Synced Sep 22, 2026, 7:17 PM EDT
Not listed Phase 2 Interventional

Bromelain, Comosain as a New Drug for Treating and Preventing Various Types of Cancer in the Humans

NCT02340845
View directory record Official record
Conditions
Cancer
Interventions
Bromelain and Comosain
Biological
Lead sponsor
Oeyama-Moto Cancer Research Foundation
Other
Eligibility
18 Years to 85 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
West Covina, California
Source: ClinicalTrials.gov public record
Updated Jan 18, 2015 · Synced Sep 22, 2026, 7:17 PM EDT
Completed Phase 1 Interventional

Pembrolizumab and Docetaxel or Gemcitabine Hydrochloride in Treating Patients Urothelial Cancer

NCT02437370
View directory record Official record
Conditions
Metastatic Urothelial Carcinoma of the Renal Pelvis and Ureter, Recurrent Bladder Carcinoma, Recurrent Urothelial Carcinoma of the Renal Pelvis and Ureter, Regional Urothelial Carcinoma of the Renal Pelvis and Ureter, Stage III Bladder Urothelial Carcinoma, Stage III Urethral Cancer, Stage IV Bladder Urothelial Carcinoma, Stage IV Urethral Cancer, Urethral Urothelial Carcinoma
Interventions
Pembrolizumab, Docetaxel, Gemcitabine Hydrochloride
Drug
Lead sponsor
University of California, Davis
Other
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated Oct 17, 2022 · Synced Sep 22, 2026, 7:17 PM EDT
Completed Phase 3 Interventional

Comparison of Different Combination Chemotherapy Regimens in Treating Infants With Acute Lymphoblastic Leukemia

NCT00015873
View directory record Official record
Conditions
Leukemia
Interventions
asparaginase, cytarabine, mercaptopurine, methotrexate, prednisolone, vincristine sulfate
Drug
Lead sponsor
Dutch Childhood Oncology Group
Other
Eligibility
Up to 1 Year
Enrollment
350 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2009
U.S. locations
2
States / cities
Boston, Massachusetts • Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Feb 16, 2014 · Synced Sep 22, 2026, 7:17 PM EDT
Active, not recruiting Phase 1 Interventional

Precursor B Cell Acute Lymphoblastic Leukemia (B-ALL) Treated With Autologous T Cells Genetically Targeted to the B Cell Specific Antigen CD19

NCT01044069
View directory record Official record
Conditions
Leukemia, Acute Lymphoblastic Leukemia
Interventions
gene-modified T cells targeted
Biological
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
93 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2027
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 7, 2026 · Synced Sep 22, 2026, 7:17 PM EDT
Completed Phase 3 Interventional

CP-675,206 Versus Either Dacarbazine Or Temozolomide In Patients Without Prior Therapy

NCT00257205
View directory record Official record
Conditions
Melanoma
Interventions
dacarbazine, CP-675,206, temozolomide
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older
Enrollment
655 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
55
States / cities
Huntsville, Alabama • Mobile, Alabama • Scottsdale, Arizona + 45 more
Source: ClinicalTrials.gov public record
Updated Jul 1, 2012 · Synced Sep 22, 2026, 7:17 PM EDT
Recruiting Phase 1 Interventional

R-MVST Cells for Treatment of Viral Infections in Children and Young Adults

NCT06926894
View directory record Official record
Conditions
Epstein-Barr Virus, Cytomegalovirus Infections, Adenovirus, BK Virus Infection, Immune Deficiency
Interventions
Rapidly generated virus specific T (R-MVST) cells
Drug
Lead sponsor
Monica Bhatia
Other
Eligibility
3 Months to 26 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 29, 2026 · Synced Sep 22, 2026, 7:17 PM EDT
Terminated Phase 3 Interventional Accepts healthy volunteers Results available

Study Assessing Injection Pain of Makena® (Hydroxyprogesterone Caproate Injection, 250 mg/mL) When Administered Via Subcutaneous Auto-injector vs Intramuscular Injection Via Needle and Syringe in Healthy Post-menopausal Women

NCT02937766
View directory record Official record
Conditions
Assessing Injection Pain of Makena® (Hydroxyprogesterone Caproate Injection, 250 mg/mL) in Healthy Post-menopausal Women
Interventions
Makena® (Hydroxyprogesterone Caproate Injection, 250 mg/mL)
Drug
Lead sponsor
AMAG Pharmaceuticals, Inc.
Industry
Eligibility
50 Years to 75 Years · Female only
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
1
States / cities
Pasadena, California
Source: ClinicalTrials.gov public record
Updated Apr 20, 2022 · Synced Sep 22, 2026, 7:17 PM EDT
Completed Phase 3 Interventional

Bioequivalence Study of Tiotropium Bromide Inhalation Powder

NCT05161156
View directory record Official record
Conditions
COPD
Interventions
Test Product (tiotropium bromide inhalation powder), 18 mcg of Spiriva (Reference Product), Placebo
Combination Product
Lead sponsor
Phargentis SA
Industry
Eligibility
40 Years and older
Enrollment
306 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022
U.S. locations
3
States / cities
Anderson, South Carolina • Gaffney, South Carolina • Union, South Carolina
Source: ClinicalTrials.gov public record
Updated Apr 9, 2023 · Synced Sep 22, 2026, 7:17 PM EDT
Recruiting Phase 3 Interventional

A Study of Zolbetuximab Together With Pembrolizumab and Chemotherapy in Adults With Gastric Cancer

NCT06901531
View directory record Official record
Conditions
Locally Advanced Unresectable Gastroesophageal Junction (GEJ) Adenocarcinoma or Cancer, Locally Advanced Unresectable Gastric Adenocarcinoma or Cancer, Metastatic Gastric Adenocarcinoma or Cancer, Metastatic Gastroesophageal Junction (GEJ) Adenocarcinoma
Interventions
zolbetuximab, Pembrolizumab, Capecitabine, Oxaliplatin, Folinic acid (leucovorin or local equivalent), 5-fluorouracil (5-FU), Placebo
Drug
Lead sponsor
Astellas Pharma Global Development, Inc.
Industry
Eligibility
18 Years and older
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
37
States / cities
Birmingham, Alabama • Bakersfield, California • Cerritos, California + 32 more
Source: ClinicalTrials.gov public record
Updated Sep 14, 2026 · Synced Sep 22, 2026, 7:17 PM EDT
Active, not recruiting Phase 2 Interventional

Pirtobrutinib and Venetoclax in Waldenström Macroglobulinemia

NCT05734495
View directory record Official record
Conditions
Waldenstrom Macroglobulinemia
Interventions
Pirtobrutinib, Venetoclax
Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2033
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 27, 2026 · Synced Sep 22, 2026, 7:17 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

ChoicesPlus: Reducing Alcohol- and Tobacco-Exposed Pregnancy

NCT01032772
View directory record Official record
Conditions
Alcohol Use, Smoking, Contraception
Interventions
Choices Plus, Information
Behavioral
Lead sponsor
University of Texas at Austin
Other
Eligibility
18 Years to 44 Years · Female only
Enrollment
261 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2013
U.S. locations
2
States / cities
Houston, Texas • Pasadena, Texas
Source: ClinicalTrials.gov public record
Updated Nov 24, 2015 · Synced Sep 22, 2026, 7:17 PM EDT
Completed Phase 1 Interventional

Study of CPI-006 as Immunotherapy for Hospitalized COVID-19 Patients

NCT04464395
View directory record Official record
Conditions
COVID-19
Interventions
CPI-006, Standard of Care
Drug · Other
Lead sponsor
Corvus Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
3
States / cities
El Centro, California • New York, New York • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 20, 2021 · Synced Sep 22, 2026, 7:17 PM EDT
Not listed Phase 2Phase 3 Interventional

Electromagnetic Fields Versus Placebo For Child-Pugh A and B Patients With Advanced Hepatocellular Carcinoma

NCT04797884
View directory record Official record
Conditions
Hepatocellular Carcinoma
Interventions
TheraBionic Device, Placebo Device, Quality of Life Assessment
Device
Lead sponsor
THERABIONIC INC.
Other
Eligibility
18 Years and older
Enrollment
166 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
7
States / cities
Tampa, Florida • Chicago, Illinois • Winston-Salem, North Carolina + 4 more
Source: ClinicalTrials.gov public record
Updated Jun 27, 2023 · Synced Sep 22, 2026, 7:17 PM EDT
Completed Phase 3 Interventional

A Study to Evaluate Safety and Efficacy Following Dosing of Oxycodone/Naltrexone for Treatment of Adults With Pain Following Bunionectomy Surgery

NCT02401750
View directory record Official record
Conditions
Pain
Interventions
Oxycodone Naltrexone (a), Oxycodone Naltrexone (b), Placebo
Drug
Lead sponsor
Elite Laboratories, Inc
Industry
Eligibility
18 Years to 75 Years
Enrollment
163 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015
U.S. locations
5
States / cities
Phoenix, Arizona • Pasadena, Maryland • Austin, Texas + 2 more
Source: ClinicalTrials.gov public record
Updated Aug 8, 2016 · Synced Sep 22, 2026, 7:17 PM EDT
Completed Not applicable Interventional Results available

Flexible Intubation Scope With or Without Video Laryngoscope in Supporting Endotracheal Tube Placement in Patients With Head and Neck Cancer Before Surgery

NCT03757091
View directory record Official record
Conditions
Head and Neck Neoplasm
Interventions
Laryngoscopy, Tracheal Intubation
Device · Procedure
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
143 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Feb 17, 2026 · Synced Sep 22, 2026, 7:17 PM EDT